was awarded a contract from Quintessence
Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.
QBI-139 is effective in cancer models against a broad range of solid tumors, according to Quintessence. The company plans to file an IND for QBI-139 in the first quarter. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.